Conduct disease-specific and disease-agnostic analyses
Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses. Patient data across early through metastatic disease stages are included in a majority of our datasets.Download fact sheet
20 deep disease-specific data models to meet your real-world clinico-genomic data needs
- Acute Myeloid Leukemia
- Advanced Bladder Cancer
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Diffuse Large B-Cell Lymphoma
- Advanced Endometrial Cancer
- Follicular Lymphoma
- Gastric/Esophageal/GEJ Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma
- Mantle Cell Lymphoma
- Melanoma
- Multiple Myeloma
- Non-small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Metastatic Prostate Cancer
- Renal Cell Carcinoma
- Small Cell Lung Cancer
Clinically meaningful cancer genomic data
Our linked Clinico-Genomics Database contains robust genomic profiling data across solid and liquid biopsies, utilizing circulating tumor (ct) DNA, and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.
The role of real-world data in disease-agnostic drug development
This session showcases industry perspectives highlighted by pre- and post-market use cases to discuss the value of RWE across the disease-agnostic drug development life cycle.
Generate real-world evidence across the life cycle of a drug, pre- and post-launch
Flatiron real-world data has informed key clinical development decisions, supported clinical trial data in regulatory submissions, fulfilled post-marketing commitments, and enabled market access and payer decisions.
Learn more about Flatiron product use cases
The CGDB has enabled 100+ publications with:
15+
biopharma partners
25+
clinical organizations
25+
unique journals
Systematic pan-cancer analysis of mutation– treatment interactions using large real-world clinicogenomics data
Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database
Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
Derive real-world endpoints using our validated real-world outcome variables
Real-world overall survival (rwOS)
Conduct robust survival analyses for studies that may span natural history of disease to comparative effectiveness with our validated mortality variable.
See our real-world mortality validation study
Real-world progression-free survival (rwPFS)
Analyze real-world progression-related endpoints across observational RWE studies with our validated real-world progression (rwP) variable.*
Real-world response endpoints
Analyze real-world response-related endpoints to support clinical development or regulatory decision making with our validated real-world response (rwR) variable.*
Source: